On March 27, 2026, Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company, announced the reactivation of its share repurchase program. This decision comes after a period of inactivity and reflects the Board of Directors' belief that the company's current market valuation does not accurately represent its financial strength and clinical progress. Over the past two trading days, the company has executed repurchases, utilizing the buyback program opportunistically. Following a recent financing round, Incannex reported having approximately $75 million in cash on hand and no debt, providing significant financial flexibility as it advances its clinical pipeline, including treatments for obstructive sleep apnea and generalized anxiety disorder. The company believes that its current market capitalization represents a disconnect from its underlying financial strength and the progress achieved across its clinical programs. CEO Joel Latham emphasized the importance of the buyback program in enhancing shareholder value, stating that the decision to reactivate it reflects their conviction in deploying capital strategically. The company intends to continue utilizing the buyback program based on market conditions and its broader capital requirements, with approximately $18.5 million remaining available for repurchases under the program as of December 31, 2025.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.